Compare Stocks → The asset beating inflation by 4x (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EYEGNASDAQ:FBRXNASDAQ:IMRNNASDAQ:INNTNASDAQ:SBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYEGAB Corporate Bond ETF$35.06+0.5%$1.90$1.44▼$8.18$24.54M0.13935,975 shs503 shsFBRXForte Biosciences$0.71+2.9%$0.71$0.38▼$1.11$26.02M0.4631,361 shs11,841 shsIMRNImmuron$2.52-0.8%$5.04$1.92▼$28.99$14.36M1.4818,174 shs5,230 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs105 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/A7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYEGAB Corporate Bond ETF+0.48%+0.72%-1.09%-2.28%+1,688.30%FBRXForte Biosciences+2.86%-6.60%-3.82%+17.38%-36.09%IMRNImmuron+2.42%+2.01%-6.79%+45.13%+22.71%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.84%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Have You Seen Elon’s New A.I. Device? (Picture Inside) (Ad)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat...MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte Biosciences3.2832 of 5 stars3.34.00.00.03.02.51.3IMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYEGAB Corporate Bond ETFN/AN/AN/AN/AFBRXForte Biosciences2.50Moderate Buy$2.75285.10% UpsideIMRNImmuronN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest INNT, IMRN, SBPH, EYEG, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2024FBRXForte BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.75(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYEGAB Corporate Bond ETF$10K2,454.20N/AN/A$1.26 per share27.83FBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/AIMRNImmuron$1.22M11.77N/AN/A$2.32 per share1.09INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AFBRXForte Biosciences-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)IMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/ASBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ALatest INNT, IMRN, SBPH, EYEG, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ALatest INNT, IMRN, SBPH, EYEG, and FBRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2024EYEGAB Corporate Bond ETFMonthly$0.14845/1/20245/2/20245/7/20243/28/2024EYEGAB Corporate Bond ETFMonthly$0.15724/1/20244/2/20244/5/20242/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYEGAB Corporate Bond ETF0.013.073.07FBRXForte BiosciencesN/A10.4510.45IMRNImmuronN/A8.527.79INNTInnovate BiopharmaceuticalsN/A0.350.35SBPHSpring Bank PharmaceuticalsN/A5.115.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYEGAB Corporate Bond ETF64.16%FBRXForte Biosciences77.63%IMRNImmuron0.12%INNTInnovate Biopharmaceuticals5.88%SBPHSpring Bank Pharmaceuticals17.17%Insider OwnershipCompanyInsider OwnershipEYEGAB Corporate Bond ETF58.20%FBRXForte Biosciences10.53%IMRNImmuron7.01%INNTInnovate Biopharmaceuticals7.90%SBPHSpring Bank Pharmaceuticals12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEYEGAB Corporate Bond ETF14700,0005.28 millionNot OptionableFBRXForte Biosciences936.44 million32.61 millionOptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableINNT, IMRN, SBPH, EYEG, and FBRX HeadlinesSourceHeadlineWhen will interest rates go down?thetimes.co.uk - January 31 at 12:12 PMBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canadaca.finance.yahoo.com - January 6 at 2:22 PMMan stabbed during street fight in Spring Bank Westhulldailymail.co.uk - September 29 at 8:36 AMWhen is the next Bank Holiday and how many are left in 2023?dailyecho.co.uk - August 13 at 4:35 AMSpring Bank fight involved two feuding families, police believehulldailymail.co.uk - August 8 at 3:14 PMCalls for more police patrols on Spring Bank after fight leaves three in hospitalhulldailymail.co.uk - August 8 at 10:14 AMSpring Bank fight: Six men and a woman held over shocking street violencehulldailymail.co.uk - August 7 at 5:57 AMThe mysterious structure on Spring Bank created to shoot out a beam of lighthulldailymail.co.uk - August 5 at 10:31 AMSyria’s Economic Outlook- Spring 2016worldbank.org - July 23 at 2:47 PMHoliday spending by bank’s customers jumped by 40% annually this springindependent.co.uk - July 17 at 9:22 AMHull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'hulldailymail.co.uk - June 30 at 12:00 PMSpring 2023 Layoff Tracker: Grubhub Cuts 400 Staffforbes.com - June 14 at 8:29 PMRibchester to host 36th annual Spring Bank marketlancashiretelegraph.co.uk - June 7 at 11:53 PMThree big changes for DWP benefit payments including Spring Bank Holidaybirminghammail.co.uk - June 2 at 7:19 PMWhat shops are open this spring bank holiday Monday 2023?metro.co.uk - May 30 at 9:46 AMDWP benefit payment date changes over Spring bank holiday weekendmetro.co.uk - May 28 at 9:06 AMWhen is the the next UK Bank Holiday and how many are left in 2023?uk.news.yahoo.com - May 20 at 4:36 PMWorld Bank, IMF Spring Meetings 2023: What did FMs, central bank governors discuss?moneycontrol.com - April 23 at 3:11 PMThe three bank holidays in May as King's Coronation approachesmanchestereveningnews.co.uk - April 23 at 3:11 PMKing's Coronation bank holiday weekend could get workers 10 days off with just 4 days leavemanchestereveningnews.co.uk - April 21 at 11:06 PMIMF and World Bank Spring Meetings, NRA-ILA Leadership Forum, UN in Libya, and Morecfr.org - April 18 at 9:11 AMWorld Bank, IMF spring meetings get underway in complex economic environmentchannelnewsasia.com - April 18 at 9:11 AMSpring sales 2023: Best deals to shop this Easter bank holidayaol.co.uk - April 10 at 10:13 AMWhen are the bank holidays around the King's coronation?manchestereveningnews.co.uk - April 8 at 10:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.